DefEYE, Inc. announced that Biovance 3L Ocular is a tri-layered, decellularized human amniotic membrane with a preserved natural epithelial basement membrane and an intact extracellular matrix structure.
Public source
Publisher name
Public post
For optometrists and ophthalmologists considering amniotic membrane in ocular surface care and surgery, understanding product design starts with understanding what the t…
Company
DefEYE, Inc.
Elevating the advancement of ocular surface disease and ocular surgery
- Industry
- Pharmaceutical Manufacturing
- Location
- Sarasota, US
- Company size
- 11–50 employees
About DefEYE, Inc.
DefEYE™, Inc. (formerly Verséa™ Ophthalmics) is a rapidly growing ocular company on a mission to transform and personalize therapeutic approaches in eye care. The company focuses on delivering a portfolio of innovative decellularized biologic solutions that optimize treatment and management of various eye care conditions, including ocular surface diseases, pterygium surgery, and other surgical interventions. Backed by deep scientific expertise, clinical rigor, and a patient-first mindset, DefEYE partners with leading eye care professionals to deliver meaningful advances that transform outcomes and elevate standards of care. To learn more, visit: www.defeye.com
See moreLatest activity
Latest activity from DefEYE, Inc.
4 signals
Products & Services
DefEYE, Inc. offers decellularized basement membrane (DBM) technology for eye care professionals managing ocular surface disease.
Products & Services
DefEYE, Inc. featured a case study of Beth Samenuk and Rohin Vij performing removal of Salzmann’s nodules using Biovance 3L Ocular.
Products & Services
DefEYE, Inc. and Biovance 3L Ocular were represented in another ophthalmic surgical setting and supported physicians incorporating DBM, a new category of AMT, into their practices.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
Cellution Biologics Inc.
Cellution Biologics Inc. released AmCoreMatrix FD, a lyophilized Human Amnion Intermediate Layer Chorion Membrane Allograft designed for surgical procedures.
Products & Services
VISUfarma - the eye health company
VISUfarma - the eye health company launched the Self Care September portfolio to help clinicians build practical routines for dry eye care profiles.
Products & Services
Harrow
Harrow re-launched VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% last week to address vernal keratoconjunctivitis underdiagnosis and undertreatment.
Products & Services
Allotex
Allotex announced that TransForm™ is available for clinical use outside the United States and is not available for distribution in the United States.
Products & Services
RVL Pharmaceuticals